Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation
Open Access
- 8 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Pharmacologica Sinica
- Vol. 42 (11), 1821-1833
- https://doi.org/10.1038/s41401-020-00601-4
Abstract
Accumulating evidence shows that agents targeting gut dysbiosis are effective for improving symptoms of irritable bowel syndrome (IBS). However, the potential mechanisms remain unclear. In this study we investigated the effects of berberine on the microbiota-gut-brain axis in two rat models of visceral hypersensitivity, i.e., specific pathogen-free SD rats subjected to chronic water avoidance stress (WAS) and treated with berberine (200 mg· kg−1 ·d−1, ig, for 10 days) as well as germ-free (GF) rats subjected to fecal microbiota transplantation (FMT) from a patient with IBS (designated IBS-FMT) and treated with berberine (200 mg· kg−1 ·d−1, ig, for 2 weeks). Before the rats were sacrificed, visceral sensation and depressive behaviors were evaluated. Then colonic tryptase was measured and microglial activation in the dorsal lumbar spinal cord was assessed. The fecal microbiota was profiled using 16S rRNA sequencing, and short chain fatty acids (SCFAs) were measured. We showed that berberine treatment significantly alleviated chronic WAS-induced visceral hypersensitivity and activation of colonic mast cells and microglia in the dorsal lumbar spinal cord. Transfer of fecal samples from berberine-treated stressed donors to GF rats protected against acute WAS. FMT from a patient with IBS induced visceral hypersensitivity and pro-inflammatory phenotype in microglia, while berberine treatment reversed the microglial activation and altered microbial composition and function and SCFA profiles in stools of IBS-FMT rats. We demonstrated that berberine did not directly influence LPS-induced microglial activation in vitro. In both models, several SCFA-producing genera were enriched by berberine treatment, and positively correlated to the morphological parameters of microglia. In conclusion, activation of microglia in the dorsal lumbar spinal cord was involved in the pathogenesis of IBS caused by dysregulation of the microbiota–gut–brain axis, and the berberine-altered gut microbiome mediated the modulatory effects of the agent on microglial activation and visceral hypersensitivity, providing a potential option for the treatment of IBS.Keywords
This publication has 68 references indexed in Scilit:
- Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed RatsPLOS ONE, 2012
- Transcriptome Analysis of the Octopus vulgaris Central Nervous SystemPLOS ONE, 2012
- Serum and Colonic Mucosal Immune Markers in Irritable Bowel SyndromeThe American Journal of Gastroenterology, 2012
- Adult hippocampal neurogenesis buffers stress responses and depressive behaviourNature, 2011
- Regional Gray Matter Density Changes in Brains of Patients With Irritable Bowel SyndromeGastroenterology, 2010
- Berberine suppresses neuroinflammatory responses through AMP‐activated protein kinase activation in BV‐2 microgliaJournal of Cellular Biochemistry, 2010
- Role of Spinal Microglia in Visceral Hyperalgesia and NK1R Up-Regulation in a Rat Model of Chronic StressGastroenterology, 2009
- Characterizing a model human gut microbiota composed of members of its two dominant bacterial phylaProceedings of the National Academy of Sciences of the United States of America, 2009
- Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed ratGut, 2008
- Microglia: a newly discovered role in visceral hypersensitivity?Neuron Glia Biology, 2006